Antibody Drug Therapy to Treat COVID-19

What is monoclonal antibody therapy?

When you have a virus, your immune system creates antibodies to help fight off the virus. Monoclonal antibody drug therapy contains man-made antibodies that are similar (clones) to the antibodies your immune system makes. Monoclonal antibody drug therapy is investigational medicine for patients who have tested positive for COVID-19 and meet certain criteria.

Who may be eligible for this treatment option?

Patients who test positive for COVID-19, have mild to moderate symptoms and are not hospitalized or requiring new oxygen therapy or an increase in oxygen therapy due to COVID-10 may be eligible for this treatment option. Patients must be 12 years of age or older, weigh at least 88 pounds (40 kg) and be at high risk for developing severe COVID-19 and/or needing hospitalization. It must be administered within 10 days of the first symptoms of COVID-19.

What factors may put you at risk?

  • Age (65 years of age and older)
  • Obesity (Body mass index (BMI) of 25 or higher, or if age 12-17, have a BMI higher than 85 percent of patients your same age or gender
  • Pregnancy
  • Chronic kidney disease
  • Diabetes
  • Immunosuppressive disease or immunosuppressive treatment
  • Cardiovascular disease (including congenital heart disease) or hypertension
  • Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
  • Sickle cell disease
  • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
  • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19))

Is antibody therapy a vaccine?

Both antibody therapy and vaccines can help offer protection from COVID-19, but they are different. Antibody therapy can help a patient who is sick with COVID-19 fight off the infection. A vaccine offers protection from future viruses but cannot treat a patient who is already sick.

How is antibody therapy given to a patient?

Antibody therapy is given through a vein (intravenous or IV) in one dose for at least 1 hour. The total appointment takes about 3 hours.

Are these COVID-19 antibody drugs approved by the U.S. Food and Drug Administration?

In November 2020, the U.S. Food and Drug Administration (FDA) authorized the emergency use of these antibody drug therapies only during the COVID-19 pandemic. This authorization is different than FDA approval. These drugs are investigational and still being studied, so there is limited information known at this time about their safety and effectiveness.

What are names of antibody therapy drugs?

Some names for antibody drugs may include bamlanivimab plus etesevimab or casirivimab plus imdevimab.

Who should I contact if I’m interested in receiving a COVID-19 antibody drug therapy?

If you are interested in receiving this therapy, you can call UW Health’s COVID-19 antibody hotline at (608) 720-3319.

Bamlanivimab and Etesevimab Fact Sheet for Patients, Parents and Caregivers

Casirivimab + Imdevimab Fact Sheet for Patients, Parents, and Caregivers

Parking directions for patients with scheduled appointments (pdf)